Abstract
Hepatitis B infection (HBV) affects 300 million people in the world, most of whom (75%) are Asian. It is one of the major causes of mortality and morbidity. The spontaneous remission rate for untreated HBV infection is approximately 80%, but the likelihood of chronic hepatitis approaches 90% if patients are infected early in life.
References
Evans AA, Fine M, London WT. Spontaneous seroconversion in hepatitis B e antigen-positive chronic hepatitis B: implications for interferon therapy. J Infect Dis 1997;176:845-850. Available from: https://doi.org/10.1086/516538
Krogsgaard K, Marcellin P, Trepo C, et al. Pre-treatment with prednisolone enhances the effect of human lymphablastoid interferon in chronic hepatitis B. Ugeskr Laeger 1998;160(39):5657-5661
Ikeda K, Saitoh S, Suzuki Y, et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus. A pilot study Cancer 1998;82:827-835. Available from: https://doi.org/10.1002/(sici)1097-0142(19980301)82:5<827::aid-cncr5>3.0.co;2-g
Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against re-infection in liver transplantation for hepatitis B cirrhosis. Lancet 1996;348: 1212-1215. Available from: https://doi.org/10.1016/s0140-6736(96)04444-3
Dore GJ, Kaldor JM, McCaughan GW. Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. BMJ1997;315:333-337. Available from: https://doi.org/10.1136/bmj.315.7104.333
McHutchinson JG, Gordon SC, Schiff ER, et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New Eng J Med 1998;339(21):1485-1492. Available from: https://doi.org/10.1056/NEJM199811193392101
Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. New Eng J Med 1998;339(21):1493-1499. Available from: https://doi.org/10.1056/NEJM199811193392102
Barbaro G, Di Lorenzo G, Belloni G, et al. Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon therapy: a randomised trial. Am J Med 1999;107(2):112-118. Available from: https://doi.org/10.1016/s0002-9343(99)00160-6
Brillanti S, Foli M, Di Tomaso M, et al. Pilot study of triple therapy for chronic hepatitis C in interferon alpha non- responders. Ital J Gastroenterol Hepatol 1999;31(2):130-134
Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and it incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatol 1998;27(5):1394-1402. Available from: https://doi.org/10.1002/hep.510270529
Benvegnu L, Chemello L, Noventa F, et al. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998;83(5):901-909. Available from: https://doi.org/10.1002/(sici)1097-0142(19980901)83:5<901::aid-cncr15>3.0.co;2-z
Yamada R, Kishi K, Sato M, et al. Transcatheter arterial chemoembolisation (TACE) in the treatment of unresectable liver cancer World J Surg 1995;19:795-800. Available from: https://doi.org/10.1007/BF00299773
Lai CL, Lau JYN, Wu PC, et al. Recombinant interferon alpha in inoperable hepatocellular carcinoma: a randomised controlled trial. Hepatol 1993;17(3):389-394
Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Eng J Med 1996;334(13):815-820. Available from: https://doi.org/10.1056/NEJM199603283341302